Big News in Small Fiber Neuropathies

Charles E. Argoff, M.D.
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center

Disclosure

■ Consultant/Independent Contractor: Pfizer, Lilly, Regeneron, Teva, US World Meds, Collegium, Kaleo, Quest, Vertex, Novartis

■ Grant/Research Support: Vertex, Gruenenthal

■ Honoraria: Allergan, BDSI, DSI, AZ, Agmen, Teva, Novartis
■ Shareholder: Pfizer, Depomed
■ Other/Royalty: Elsevier, Cambridge Press
Presentation Objectives

- Describe the definition of small fiber polyneuropathy
- Explain approaches to making the diagnosis of small fiber polyneuropathy
- List the range of medical conditions associated with small fiber polyneuropathy
- Describe current and emerging treatments of small fiber polyneuropathy

Background

- Peripheral neuropathy is experienced by approximately 40 million people in the US
- Many peripheral neuropathies are mixed neuropathies with both large fiber and small fiber involvement
- Increasingly recognized is the demonstration of specific involvement of small myelinated or unmyelinated fibers, e.g. small fiber neuropathies
What is Neuropathic Pain?

- Pain arising as a direct consequence of diseases affecting the somatosensory system.
  
  Grading system: definite, probable, possible
  

- In Plain English: Pain from the nerves, spinal cord, or brain. Not originating in the bones, muscles, organs.

Which person has pain?
### Differential diagnosis - Widespread or Difficult to Diagnose Localized Pain

- **Rheumatic**
  - Arthritis (OA, RA)
  - Polymyalgia Rheumatica
  - Osteomalacia
  - Myopathy
  - Spondyloarthropathies
  - Systemic Lupus Erythematosus

- **Endocrine**
  - Hypothyroidism
  - Diabetes

- **Neurologic**
  - Multiple sclerosis
  - Chiari malformation
  - Spinal stenosis
  - Radiculopathy
  - Polyneuropathy
  - Fibromyalgia

- **Other**
  - SMALL FIBER POLYNEUROPATHY?

### Common Neuropathic Pain Diagnoses

- Diabetic Peripheral Neuropathy*
- Post Herpetic Neuralgia*
- Radicular Pain (neuropathic low back pain)
- Traumatic Peripheral Nerve Injury
- Complex Regional Pain Syndrome
- Chronic Postop Pain
- Phantom Limb Pain
- HIV related neuropathy
- Spinal Cord Injury*
- Post-stroke pain
- Trigeminal Neuralgia*
- Small Fiber Polyneuropathy

* FDA approved medications available
Polyneuropathies may involve small and large nerve fibers

<table>
<thead>
<tr>
<th></th>
<th>Large-fiber neuropathy</th>
<th>Small-fiber neuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptoms</strong></td>
<td>Numbness, pins and needles, tingling, poor balance</td>
<td>Pain: burning, electric shocks, stabbing pain, numbness</td>
</tr>
<tr>
<td><strong>Exam Findings</strong></td>
<td>Reflexes, proprioception Vibration, +/- motor</td>
<td>Thermal, pin-prick sensation, allodynia</td>
</tr>
<tr>
<td><strong>Functional changes</strong></td>
<td>Pressure, balance, fall risk</td>
<td>Nociception; protective sensation</td>
</tr>
<tr>
<td><strong>Diagnostic test</strong></td>
<td>EMG/NCV, sural nerve biopsy</td>
<td>QST, nerve biopsy, Intraepidermal nerve fiber density (skin biopsy)</td>
</tr>
</tbody>
</table>

Small Fiber Polyneuropathy Definition and Key Facts

- Small fiber neuropathies (SFN) result from damage to the peripheral nerves affecting small myelinated A-Delta and unmyelinated C fibers.
- The fibers affected include both small somatic as well as autonomic fibers
- Thermal perception and nociception are subserved by small fibers
- Enteric function is also subserved by small fibers
- LARGE fibers are heavily myelinated and involved in muscle control, as well as touch, vibration adn position sense

Small Fiber Polyneuropathy Definition and Key Facts-2

- Most SFNs occur in a length-dependent fashion – first stocking distribution changes and then later glove distribution
- Less common but no longer rare, non-length dependent SFN can result in symptoms involving the face, trunk, proximal limbs, or other more localized areas
- The pathogenesis of injury to small fibers is not well understood


Small Fiber Polyneuropathy Definition and Key Facts-3

- SFN can progress to involve large fibers as well
- Muscle cramps may be one of the presenting complaints of SFN
- Epidemiologic data from the Netherlands suggest a minimum incidence of 12/100,000 people
- Children also can experience SFN- the diagnosis may be more challenging in adults as will be discussed later

Small Fiber Polyneuropathy: BIG impact on quality of life

- In one study that measured the impact specifically on SFPN on quality of life, 265 patients enrolled
- SFN-SIQ, VAS, 36 item short form health survey evaluated
- SFPN patients demonstrated a marked overall reduction in quality of life
- Physical and mental measures were decreased
- Other reported data suggests significant direct and indirect healthcare costs with increasing levels of pain in idiopathic SFN


Disorders Associated with SFN

- Diabetes
- Impaired Glucose Tolerance
- Metabolic Syndrome
- Sarcoidosis
- Thyroid Dysfunction
- HIV
- Vitamin B12 Deficiency
- Vitamin B1 Deficiency
- Chemotherapy drugs
- Antiviral Agents
- Celiac Disease
- Sjogren's Syndrome
- Paraneoplastic Syndromes
- Paraproteinemias
- Rheumatoid Arthritis
- Idiopathic (up to 50%)
Disorders Associated with SFN-2

- Guillain-Barre Syndrome
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Restless Leg Syndrome
- Hepatitis C
- Systemic Lupus Erythematosus
- Amyloidosis
- Fabry’s Disease
- Ehlers Danlos Syndrome
- Hereditary Sensory Neuropathies
- Hereditary Autonomic Neuropathies
- Central post stroke pain


Disorders associated with SFN-3

- Alcohol use
- Rabies, varicella or Lyme vaccine
- Anti-TNF inhibitors
- Metronidazole
- Linezolid
- Statins
- Sodium channelopathies
- Parkinson disease
- Pompe disease
- Wilson disease
- ALS
- Fragile X
- X linked adrenoleukodystrophy
- Chronic renal disease

SFN Pathophysiology- Possible role of Sodium Channel mutations

- Genetic variants in the structure/function of sodium channels may lead to either loss of pain sensitivity or enhanced pain
- Inactivating mutations in SCN9A, which encodes Nav1.7 is associated with congenital insensitivity to pain
- Gain of function mutations in SCN9A may result in SFN
- Various mutations in TRPA1 or NAV1.8(SCN10A) and Nav1.9 (SCN11A) also may lead to SFN
- Might this information lead to new treatments?


SFN Symptoms

- Symptoms vary widely in severity
- Often affected individuals describe a gradual onset of vague distal sensory disturbances
- Examples include feeling like there is sand in the person’s shoe, a sock feeling as if it has pebbles in it, pins and needle sensations, cold painful sensations or tingling.

SFN Symptoms - 2

- Burning pain in the extremities, sometimes severe
- Allodynia and hyperesthesia
- Socks or bedsheets may be painful
- Symptoms are often worse at night


SFN Symptoms - 3

- Autonomic and enteric dysfunction including: dry eyes, dry mouth, lightheadedness with changes in posture, syncope, abnormalities of sweating, erectile dysfunction, GI symptoms such as nausea and emesis, constipation, diarrhea, changes in urinary frequency including nocturia.

SFN- Diagnosis

- Normal or practically normal basic physical and neurological examination!!!
- However, possible findings include decreased pin prick, diminished thermal sensation, hyperalgesia, dry skin
- A detailed history is vital to making the diagnosis
- Ancillary testing may be helpful as well


Common Diagnostic Studies and Limitations

**Studies**

- Blood studies
- X-ray, CT, MRI
- Electromyography (EMG)
- Nerve conduction velocity (NCV)
- *Quantitative sensory testing (QST)*
- *Skin biopsy*

**Limitations of EMG/NCV**

- Insensitive in acute injury
- Normal result does not rule out neuropathic pain
- Cannot assess function of small-fiber nerves involved in most neuropathic pain

SFN-Diagnosis-additional information

- Various written tools such as the Neuropathic Pain Symptom Inventory may be helpful
- Quantitative Sensory Testing - this can detect thresholds of thermal pain, thermal sensation and vibration for example. Contact Heat Evoked Potentials attempts to link peripheral activation to central.
- Quantitative Sudomotor Axon Reflex testing (QSART)

SFN-Diagnosis-Skin Biopsy

- Skin Biopsy - this has become widely accepted as a technique to evaluate the structure of small nerve fibers.
- The standard is a 3-mm skin punch biopsy that can be taken from anywhere over the body.
- Due to the need to compare to normal values the lower extremity is most commonly assessed (also length dependent SFN more common than non-length dependent)
- The results are expressed as the number of intraepidermal fibers per mm
- The sensitivity (78-92%) and specificity (65-90%) is fairly high for this technique
SFN-Skin Biopsy- 2

- Intraepidermal nerve fibers (IENF) are unmyelinated sensory endings that arise from the sub-papillary dermis
- They widely express the TRPV1 receptor - this means they are distal nociceptors
- One of the more common areas to perform a skin biopsy for diagnostic purposes is 10 cm proximal from the lateral malleolus
- Using antibodies against the protein gene product (PGP 9.5), a cytoplasmic ubiquitin carboxyl-terminal hydrolase, the number of fibers crossing the dermal-epidermal junction can be quantified – measured as IENF/millimeter


SFN-Skin Biopsy- 3

- Studies have demonstrated stability of IENFD in normal controls as well as in patients with idiopathic SFN when re-biopsied in the same sensory territory after 3 weeks
- IEFND decreases with age in SNF associated with various etiologies
- IEFND has been found to be decreased in non-painful disorders such as Parkinson's disease, ALS, critical illness and peripherhal arterial disease - more to be discussed!

Loss of skin nerve fibers in PHN

- CCM visualizes the C-fibers originating from the trigeminal nerve that travel to the Bowman’s membrane of the cornea.
- CCM software can quantify: corneal nerve fiber density (CNFD), corneal nerve fiber tortuosity, corneal nerve branch density, corneal nerve fiber length.
- Studies support that patients with both non-length dependent as well as length dependent SFN demonstrate a decrease in CNFD.

SFN- Diagnosis-Corneal Confocal Microscopy (CCM)

Functional and Imaging Assessment of Small Nerves

- Quantitative Sensory Testing
- Microneurography
- Nociceptive Evoked Potentials
- Peripheral Nerve Ultrasound
- Magnetic Resonance Imaging


Small fiber polyneuropathy - blood/other tests

- Metabolic: thyroid functions, HbA1C, FBS
- Nutritional: CBC, Hepatic Profile, Vitamin B1 and B12
- Infectious: CRP, HIV, Lyme, HBV, HCV
- Autoimmune: ESR, ANA, Anti-ENA, ANCA, anti-gliadin, RF, serum ACE, ? CXR
- Paraneoplastic: Tumor markers, LDH, Myeloma screen, SPE, anti-Hu and anti-CV2/CRMP-5 ab

Small fiber polyneuropathy - blood/other tests (continued)

- Neurotoxins: urine and blood toxicology, review drug history
- Hereditary: alpha-galactosidase A, globotriaosylceramide levels, renal panel, urine protein, genetic testing for SCN9A or SCN10A
- Lumbar puncture: if you suspect inflammatory, auto-immune or paraneoplastic etiologies


More about voltage gated sodium channelopathies

- $Na_v1.7$ and $Na_v1.8$ gain of function mutations in inherited erythromelagia
- $Na_v1.7$ in paroxysmal extreme pain disorder - paroxysmal rectal, ocular or submandibular pain with flushing with possible autonomic dysfunction - 10 gain of function mutations have been identified
- $Na_v1.7$, $Na_v1.8$ and $Na_v1.9$ gain of function mutations in SFN

"Discouraging Data on the Antidepressant (AS WELL AS MANY OTHER TREATMENTS)"

Gabapentin in the treatment of painful diabetic neuropathy*

- Placebo
- Gabapentin

N=165

*Not approved by FDA for this use  †P <0.01; †P <0.05

SFN- Treatment

- Treat the treatable! If an underlying cause of SFN can be determined, optimal treatment of the causative condition may lessen the symptoms of SFN
- Few studies and no guidelines have examined the pharmacologic treatment of the pain associated with SFN
- In one such study, both gabapentin and tramadol were found to be effective for SFN


Neuropathic pain recommendations of various societies

<table>
<thead>
<tr>
<th>EFNS, Europe Neurology</th>
<th>Canadian Pain Society</th>
<th>IASP NeuPSIG</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First line</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCA</td>
<td>TCA</td>
<td>TCA, SNRI</td>
</tr>
<tr>
<td>GBP/PGB</td>
<td>GBP/PGB</td>
<td>GBP/PGB</td>
</tr>
<tr>
<td>Lidocaine 5% plaster</td>
<td></td>
<td>Lidocaine 5%</td>
</tr>
<tr>
<td><strong>Second line</strong></td>
<td></td>
<td>(specific circumstances)</td>
</tr>
<tr>
<td>SNRI (Opioid)</td>
<td>SNRI (Opioid)</td>
<td>Opioid</td>
</tr>
<tr>
<td></td>
<td>Lidocaine 5%</td>
<td>Opioid</td>
</tr>
<tr>
<td><strong>Third line</strong></td>
<td></td>
<td>Tramadol</td>
</tr>
<tr>
<td>Opioid</td>
<td>Opioid (except methadone)</td>
<td>Paroxetine</td>
</tr>
<tr>
<td>Lamotrigine Capsaicin</td>
<td></td>
<td>Bupropion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NMDA antagonist</td>
</tr>
<tr>
<td><strong>Fourth line</strong></td>
<td></td>
<td>Methadone</td>
</tr>
<tr>
<td>EFNS, European Federation of Neurological Societies; IASP, International Association for the Study of Pain; NeuPSIG, Neuropathic Pain Special Interest Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SFN- Is IVIG (intravenous immunoglobulin) an Emerging Treatment?

- A recent report described 3 patients with sarcoidosis and SFN who were experiencing severe pain as well as dysautonomia
- Each patient had biopsy proven SFN
- Each patient had failed to response to "conventional" analgesic/symptomatic approaches
- Each patient received an initial dose of IVIG 2g/kg followed by 1g/kg doses at regular intervals- each with dramatic resolution of pain and autonomic symptoms
- Further larger studies are warranted


SFN- Is IVIG (intravenous immunoglobulin) an Emerging Treatment?-2

- Limited data for Sjogren's syndrome- IVIG 2g/kg
- Juvenile onset unexplained widespread pain treated with IVIG in 15 patients by Oaklander et al- treated at 2g/kg/month at least 3 times- 62% demonstrated significant improvement
- In another study, 46 patients with SFPN associated with dysautonomia were treated with one or more IVIG treatment- for patients with pain intensity levels ≥ 3 or with significant dysautonomia, the treatment was helpful

SFN- Is IVIG (intravenous immunoglobulin) an Emerging Treatment?-3

- 55 patients with “apparently autoimmune” small-fiber polyneuropathy treated with IVIG
- IVIG treatment duration averaged 28 +/- 25 months
- Improvements were noted in autonomic function testing, pain reduction, sweat production
- 16% of patients were considered in remission after multiple treatments

Liu X et al. IVIG for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety The Adv Neurol Disord 2018 Jan 8

SFPN and Fibromyalgia

- Approximately 50% of patients who have been diagnosed with Fibromyalgia in several published studies have demonstrated findings consistent with SFPN on diagnostic biopsies- studies to be reviewed on subsequent slides
- What does that mean?
- What does that mean about interpreting FM studies that have already been published?
CWP, SFPN and Fibromyalgia I

- 27 patients with fibromyalgia who satisfied the 2010 ACR criteria were compared to 30 matched controls
- 41% of skin biopsies from fibromyalgia subjects compared to 3% from controls were diagnostic for SFPN
- The Michigan Neuropathy Screening Instrument and Utah Early Neuropathy Scale scores were higher in fibromyalgia patients


CWP, SFPN and Fibromyalgia II

- 25 patients with fibromyalgia were compared to 10 depressed patients and controls
- Small fiber evaluation included QST, pain-related evoked potentials and quantified intraepidermal nerve fiber density and regenerating IENF of the lower leg and upper thigh
- Compared with control subjects fibromyalgia patients BUT not depressed patients had impaired small fiber function

CWP, SFPN and Fibromyalgia II (continued)

- Skin biopsy findings demonstrated that total and regenerating IENFs at the lower leg and upper thigh were reduced in patients with fibromyalgia compared with controls
- A reduction in unmyelinated nerve fiber bundles was seen in patients with fibromyalgia compared with depressed and control subjects
- The authors concluded that the results point towards a neuropathic nature of fibromyalgia.


Complex chronic pelvic pain and SFN

- Retrospective study with objective to demonstrate the prevalence of SFN in patients with refractory chronic pelvic pain
- 25/39 patients (64%) demonstrated skin biopsy findings consistent with SFN
- Co-morbid conditions noted included GERD (46%), migraine (38%), IBS (33%), fibromyalgia (38%), endometriosis (15%), interstitial cystitis (18%), vulvodynia (5%), other chronic pain syndromes (36%)

Chen A, De E, Argoft C. Pain Med 2018 Feb 13
Patient Education

Summary

- Multiple medical conditions are associated with SFN including many considered common
- The mechanism(s) of SFN are not completely understood and may vary depending on the individual/specific associated disorder
- Recognizing SFN and its existence in perhaps more conditions than previously recognized may lead to improved treatment approaches